Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
DenmarkIPO:
01 June 2009Website:
http://www.genmab.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 21:40:16 GMTDividend
Analysts recommendations
Institutional Ownership
GMAB Latest News
Company Announcement Net sales of DARZALEX ® in the third quarter of 2024 totaled USD 3,016 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson & Johnson were USD 3,016 million in the third quarter of 2024. Net trade sales were USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world.
Genmab (GMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Incyte (INCY). But which of these two stocks presents investors with the better value opportunity right now?
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Baillie Gifford & Co has informed us that, as of October 3, 2024, Baillie Gifford & Co held the voting rights to 3,301,530 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics.
Media Release COPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed across FRα expression levels Phase 3 trial will further evaluate the safety and efficacy of Rina-S at 120 mg/m 2 in patients with advanced ovarian cancer Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate (ADC), demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W), regardless of FRα expression levels. These data were from the dose expansion part of a multi-part study evaluating the safety and efficacy of single-agent Rina-S in ovarian cancer (OC) and endometrial cancer (EC).
Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy COPENHAGEN, Denmark; August 19, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU), as well as the European Economic Area (EEA) countries (Iceland, Liechtenstein, Norway) and Northern Ireland.
Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ) would become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy COPENHAGEN, Denmark; June 28, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of conditional marketing authorization of epcoritamab (TEPKINLY®), a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The final European Commission decision on this indication for epcoritamab is anticipated later this year.
Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. With this approval, EPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in the U.S. to treat this patient population. This indication is approved.
- 1(current)
- 2
What type of business is Genmab A/S?
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
What sector is Genmab A/S in?
Genmab A/S is in the Healthcare sector
What industry is Genmab A/S in?
Genmab A/S is in the Biotechnology industry
What country is Genmab A/S from?
Genmab A/S is headquartered in Denmark
When did Genmab A/S go public?
Genmab A/S initial public offering (IPO) was on 01 June 2009
What is Genmab A/S website?
https://www.genmab.com
Is Genmab A/S in the S&P 500?
No, Genmab A/S is not included in the S&P 500 index
Is Genmab A/S in the NASDAQ 100?
No, Genmab A/S is not included in the NASDAQ 100 index
Is Genmab A/S in the Dow Jones?
No, Genmab A/S is not included in the Dow Jones index
When was Genmab A/S the previous earnings report?
No data
When does Genmab A/S earnings report?
The next expected earnings date for Genmab A/S is 06 November 2024